Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Stock forecast & fair value
NewAmsterdam Pharma Co N.V. (NAMS) stock forecast and price target
NewAmsterdam Pharma Co N.V. (NAMS) trades at $18.90. 14 analysts' median price target is $50.53 (+167%), from $37.83 to $59.00.
NewAmsterdam Pharma Co N.V.'s latest quarter
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for NAMS stock?
The median of 14 analysts' 12-month targets is $50.53, +167% from $18.90; the range is $37.83 to $59.00. The average rating is strong buy.
Does NewAmsterdam Pharma Co N.V. usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is NAMS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.